Gilead Sciences (GILD) reported another strong quarter with earnings per share coming in at $0.90, well above the Zacks Consensus Estimate of $0.82 and the year-ago quarter’s earnings of $0.59. For the full year, the company reported a 31% growth in revenues.

We remain optimistic about growth of HIV/AIDS franchise drugs Truvada and Atripla. Earnings over the past few quarters have consistently been above expectations, specifically on strong sales of the HIV franchise products.

Meanwhile, the worldwide panic regarding swine-flu boosted the reported quarter’s royalty income, a trend we expect to continue, thanks to increased sales of the anti-viral drug Tamiflu. Given these factors, we upgrade the stock to Outperform.

Zacks Investment Research

1. (GILD) Gilead Sciences Suffers Stage III SetbackGilead Sciences (GILD) received a major pipeline setback with disappointing results from a phase III...
2. (GILD) Gilead Sciences Closer to FDA ApprovalGilead Sciences, Inc (GILD) received a positive opinion from the Anti-Infective Drugs Advisory Committee of...
3. (GILD) Gilead Sciences-GlaxoSmithKline Deal Targets AsiaRecently, Gilead Sciences (GILD) entered into a licensing agreement with GlaxoSmithKline (GSK) to commercialize Viread...
4. (GILD) Gilead Sciences Awaits Committee OutcomeGilead Sciences, Inc (GILD) is awaiting the outcome of the Anti-Infective Drugs Advisory Committee of...
5. (GILD) Gilead Sciences’ Strong PerformanceGilead Sciences (GILD) posted strong third quarter results yesterday. The company’s earnings per share of...
6. (GILD) Gilead Sciences – estimates have continued to tick higher over the last few monthsGilead Sciences, Inc.’s (GILD) share price continues to head north in response to higher estimates...

Search Posts by Tag: GILD | Gilead Sciences Inc | Biotechnology | Healthcare

RSS Feeds by Tag: GILD | Gilead Sciences Inc | Biotechnology | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author